Aktarım Tamamlandı — 

Biosimilar infliximab use in paediatric IBD

BACKGROUND: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. ME...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arch Dis Child
Asıl Yazarlar: Richmond, Lisa, Curtis, Lee, Garrick, Victoria, Rogers, Pam, Wilson, Michelle, Tayler, Rachel, Henderson, Paul, Hansen, Richard, Wilson, David C, Russell, Richard K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2018
Konular:
Drug Therapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754881/
https://ncbi.nlm.nih.gov/pubmed/28988215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/archdischild-2017-313404
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller